

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 8, 2018**

---

**Versartis, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36361**  
(Commission  
File Number)

**26-4106690**  
(IRS Employer  
Identification No.)

**1020 Marsh Road**  
**Menlo Park, CA 94025**  
(Address of principal executive offices, including zip code)

**(650) 963-8580**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 2.02 Results of Operation and Financial Condition**

On May 8, 2018, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three month period ended March 31, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K.

Exhibit No.	Description
99.1	Press Release, issued by Versartis, Inc. on May 8, 2018.

## INDEX TO EXHIBITS

Exhibit  
No. Description

---

99.1 [Press Release, issued by Versartis, Inc. on May 8, 2018](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 8, 2018

VERSARTIS, INC.  
(Registrant)

By: /s/ Shane Ward

Shane Ward

*Senior Vice President and General Counsel*



### Versartis Reports First Quarter 2018 Financial Results

MENLO PARK, Calif., May 8, 2018 (GLOBE NEWSWIRE) -- [Versartis, Inc.](#) (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018.

“We have undertaken additional efforts to aggressively manage our cash as we work diligently to complete our strategic review process,” said Jay Shepard, President and CEO of Versartis, Inc. “We acknowledge the patience our shareholders have shown during this process and we are committed to providing an update as soon as we can.”

#### First Quarter 2018 Financial Results

For the first quarter ended March 31, 2018, Versartis reported a net loss of approximately \$9.0 million, or \$0.25 per share, basic and diluted, compared to a net loss for the first quarter ended March 31, 2017 of \$29.7 million, or \$0.85 per share, basic and diluted.

Total operating expenses for the quarter ended March 31, 2018 were \$8.5 million compared to \$29.7 million for the quarter ended March 31, 2017. Research and development (R&D) expenses for the quarter ended March 31, 2018 were \$3.6 million, compared to \$22.0 million for the quarter ended March 31, 2017. The decrease in R&D expenses was primarily due to the termination of clinical and manufacturing related contracts that supported the company’s Phase 3 clinical trials for somavaratan following the Phase 3 VELOCITY trial failing to meet its primary endpoint.

General and administrative (G&A) expenses were \$4.9 million for the quarter ended March 31, 2018 compared to \$7.7 million for the quarter ended March 31, 2017. The decrease in G&A expenses was primarily due to the reduction in workforce and our continued efforts to reduce consulting and professional services expenses following the Phase 3 VELOCITY trial failing to meet its primary endpoint.

Total operating expenses for the quarter ended March 31, 2018 include non-cash stock-based compensation expense of \$2.8 million compared to \$3.9 million of non-cash stock-based compensation expense for the quarter ended March 31, 2017.

Cash, cash equivalents, and short-term investments were \$74.7 million as of March 31, 2018.

---

**Contacts:**

Kevin Haas

VP, Finance

(650) 963-8595

[khaas@versartis.com](mailto:khaas@versartis.com)

**Versartis, Inc.**  
**Condensed Consolidated Statements of Operations**  
**(Unaudited)**  
(in thousands, except per share amounts)

	Three Months Ended March 31,	
	2018	2017
<b>Operating expenses</b>		
Research and development	\$ 3,600	\$ 22,004
General and administrative	4,917	7,656
Total operating expenses	8,517	29,660
Loss from operations	(8,517)	(29,660)
Interest income	193	199
Other income (expense), net	(657)	(261)
Net loss	(8,981)	(29,722)
Net loss per share- basic and diluted	\$ (0.25)	\$ (0.85)
Weighted-average common shares used to compute basic and diluted net loss per share	36,019	35,004

**Versartis, Inc.**  
**Condensed Consolidated Balance Sheets**  
**(Unaudited)**  
(in thousands)

	March 31, 2018	December 31, 2017
<b>Assets:</b>		
Cash and cash equivalents	\$ 74,686	\$ 81,146
Other assets	3,594	3,743
Build-to-suit lease asset	8,829	8,888
<b>Total assets</b>	<b>\$ 87,109</b>	<b>\$ 93,777</b>
<b>Liabilities and stockholders' equity:</b>		
Accounts payable and other current liabilities	\$ 3,535	\$ 5,593
Build-to-suit lease obligation	6,944	5,428
<b>Total liabilities</b>	<b>10,479</b>	<b>11,021</b>
Total stockholders' equity	76,630	82,756
<b>Total liabilities and stockholders' equity</b>	<b>\$ 87,109</b>	<b>\$ 93,777</b>